168 related articles for article (PubMed ID: 1516889)
1. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
Wurzburger MI; Prelevic GM; Sonksen PH; Balint-Peric LA
Horm Metab Res; 1992 Jul; 24(7):329-32. PubMed ID: 1516889
[TBL] [Abstract][Full Text] [Related]
2. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes.
Wurzburger MI; Prelevic GM; Sönksen PH; Balint-Peric LA; Wheeler M
J Clin Endocrinol Metab; 1993 Jul; 77(1):267-72. PubMed ID: 8325951
[TBL] [Abstract][Full Text] [Related]
3. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
[TBL] [Abstract][Full Text] [Related]
4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
5. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
6. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
[TBL] [Abstract][Full Text] [Related]
7. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
[TBL] [Abstract][Full Text] [Related]
8. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
Valea A; Carsote M; Ghervan C; Georgescu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
[TBL] [Abstract][Full Text] [Related]
9. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy.
Hyer SL; Sharp PS; Brooks RA; Burrin JM; Kohner EM
Acta Endocrinol (Copenh); 1989 Feb; 120(2):187-94. PubMed ID: 2916380
[TBL] [Abstract][Full Text] [Related]
10. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
Osei K; O'Dorisio TM; Malarkey WB; Cataland S
J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
[TBL] [Abstract][Full Text] [Related]
12. The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus.
Würzburger MI; Prelevic GM; Sönksen PH; Peric LA; Till S; Morris RW
Clin Endocrinol (Oxf); 1990 Jun; 32(6):787-97. PubMed ID: 2200623
[TBL] [Abstract][Full Text] [Related]
13. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
Laursen T; Jørgensen JO; Orskov H; Møller J; Harris AG; Christiansen JS
Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S
Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
[TBL] [Abstract][Full Text] [Related]
16. Four years' treatment of resistant acromegaly with octreotide.
McKnight JA; McCance DR; Sheridan B; Atkinson AB
Eur J Endocrinol; 1995 Apr; 132(4):429-32. PubMed ID: 7711880
[TBL] [Abstract][Full Text] [Related]
17. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
Cheetham TD; Clayton KL; Taylor AM; Holly J; Matthews DR; Dunger DB
Clin Endocrinol (Oxf); 1994 Apr; 40(4):515-22. PubMed ID: 8187319
[TBL] [Abstract][Full Text] [Related]
18. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
[TBL] [Abstract][Full Text] [Related]
19. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers.
Aarsen RS; Bruining GJ; Grose WF; van Strik R; Lamberts SW; Harris AG
Acta Endocrinol Suppl (Copenh); 1987; 286():45-53. PubMed ID: 2892337
[TBL] [Abstract][Full Text] [Related]
20. Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus.
Orskov L; Møller N; Bak JF; Pørksen N; Schmitz O
Metabolism; 1996 Feb; 45(2):211-7. PubMed ID: 8596492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
